For instance, silencing inhibitory checkpoint molecule, such as PD-1 (PDCD1) in CAR T cells targeting CLEC12A, has been explored to overcome T-cell exhaustion and improve efficacy in AML [94] (NCT06128044). Here, CLEC12A is linked to acute myeloid leukemia.